Adaptive Cytokine- and Exosome-Based Therapy for Coexisting Vascular Dementia and Prostate Cancer: A Case Report

¹Ochanomizu Health and Longevity Clinic, Tokyo 101-0062, Japan

²Shirasawa Anti-Aging Medical Institute, Tokyo 101-0062, Japan

³Livant Neurorecovery Center, Guadalajara, Mexico

*Corresponding Author: Takuji Shirasawa, Ochanomizu Health and Longevity Clinic, Tokyo 101-0062, Japan, and Shirasawa Anti-Aging Medical Institute, Tokyo 101-0062, Japan, E-mail: [email protected]

Received Date: September 09, 2026
Published Date: September 24, 2026

Citation: Shirasawa T, Cobos LCA. (2026). Adaptive Cytokine- and Exosome-Based Therapy for Coexisting Vascular Dementia and Prostate Cancer: A Case Report. Mathews J Case Rep. 11(4):233.

Copyrights: Shirasawa T and Cobos LCA. © (2026).

ABSTRACT

Background: The coexistence of vascular dementia and prostate cancer poses therapeutic challenges because standard oncological interventions may affect cognition, whereas neuroregenerative growth factors may influence tumor biology. This report describes longitudinal cytokine- and exosome-based treatment in a patient with both conditions.

Case Presentation: A 78-year-old man presented with memory impairment and vascular risk factors, including hypertension, dyslipidemia, and type 2 diabetes mellitus. Baseline evaluation showed an MMSE score of 27/30, impaired verbal memory, slow-wave EEG activity, abnormal P300 responses, cortical and hippocampal atrophy, subcortical vascular lesions, carotid intraluminal atherosclerotic findings, and elevated PSA. He received sublingual cytokine- and exosome-based formulations, with serial cognitive testing, EEG, MRI, carotid virtual endoscopy, PSA monitoring, prostate biopsy, and bone scintigraphy.

Results: During neuroregenerative therapy, global cognitive function remained broadly stable for several years, although verbal memory later declined. Follow-up EEG demonstrated reduced slow-wave activity and interval changes in P300 responses, while MRI showed persistent cortical atrophy, resolution of some subcortical vascular abnormalities, hippocampal morphological changes, and regression of carotid intraluminal lesions. Prostate biopsy confirmed adenocarcinoma in 5 of 16 specimens, with an overall Gleason score of 4+3=7. After PSA elevation, IGF-containing formulations were replaced with an anti-oncogenic cytokine and exosome cocktail. PSA levels subsequently remained relatively stable, and MRI and bone scintigraphy showed no evidence of local invasion or bone metastasis.

Conclusion: Longitudinal observations suggest that cytokine- and exosome-based regimens may be adaptable to the competing priorities of vascular dementia and prostate cancer by removing growth-promoting components and emphasizing anti-oncogenic signaling pathways. However, this single case cannot establish efficacy or causality, and controlled studies are required to confirm these findings.

Keywords: Vascular Dementia, Prostate Cancer, Anti-Oncogenic Cytokines, Exosomes